Allergan Inc. must disclose documents it shared with two independent consultants to develop a strategy to prevent the U.S. Food and Drug Administration from allowing other drugmakers to make and sell generic versions of its tear-producing drug, Restasis.

The Ireland-based drugmaker is fighting several cases saying it schemed to extend its monopoly over a cyclosporine emulsion prescribed for dry-eye disease beyond the expiration date of its original Restasis patents. The cases have been consolidated in multidistrict litigation in the U.S. District Court for the Eastern District of New York.

The plaintiffs include pharmacies like Walgreen Co. and CVS Pharmacy Inc....